Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-20117 + capecitabine + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
HS-20117 is a fully-human bispecific IgG1-like antibody targeting both EGFR and MET. It is being developed for use in combination with other drugs for the treatment of advanced solid tumors. CAPEOX (also known as XELOX or CAPOX) is a chemotherapy regimen that combines capecitabine (an oral prodrug of 5-fluorouracil) and oxaliplatin (a platinum-based chemotherapeutic agent). This combination works by destroying rapidly dividing cancer cells through different mechanisms—capecitabine interferes with DNA synthesis while oxaliplatin causes DNA crosslinking and damage. The combination is primarily used to treat colorectal cancer but may also be used in other gastrointestinal cancers. Clinical trials are ongoing to evaluate the safety and efficacy of combining HS-20117 with CAPEOX in advanced solid tumors[1][2][4][5][6].
- Brand names
- XelodaEloxatin
- Other names
- capecitabine plus oxaliplatinCAPOXXELOX
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on HS-20117 + capecitabine + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-20117 + capecitabine + oxaliplatin.